<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00598676</url>
  </required_header>
  <id_info>
    <org_study_id>GE IDE No. S02607</org_study_id>
    <nct_id>NCT00598676</nct_id>
  </id_info>
  <brief_title>3 Limus Agent Eluting Stents With Different Polymer Coating</brief_title>
  <acronym>ISAR-TEST-4</acronym>
  <official_title>Intracoronary Stenting and Angiographic Results: Test Efficacy of 3 Limus-Eluting STents (ISAR-TEST 4): Prospective, Randomized Trial of 3-limus Agent-eluting Stents With Different Polymer Coatings</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Deutsches Herzzentrum Muenchen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Deutsches Herzzentrum Muenchen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to determine whether biodegradable polymer based rapamycin-eluting&#xD;
      stent performs equal to permanent polymer based everolimus- and rapamycin-eluting stents&#xD;
      regarding reduction of adverse cardiac events at one year.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Drug-eluting stents significantly reduce in-stent restenosis and the subsequent need for&#xD;
      target vessel revascularisation compared with bare metal stents. Although this applies to the&#xD;
      vast majority of patients, intimal hyperplasia and in-stent restenosis have not been&#xD;
      completely eliminated and remain to occur in certain high risk subgroups. Thus there is&#xD;
      ongoing research for new, potentially more effective and safe drug-eluting stent systems.&#xD;
&#xD;
      One direction of extensive research is the search of new polymers such as biodegradable&#xD;
      polymers which allow a controlled drug-release and disappear with time, reducing the&#xD;
      probability of polymer-induced chronic inflammation on the vessel wall.&#xD;
&#xD;
      Another direction is finding new drugs to suppress neointimal hyperplasia. Promising&#xD;
      preclinical and clinical results suggest that the Everolimus eluting stent platform might&#xD;
      provide potential improvements over prior generations of drug-eluting stents.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2007</start_date>
  <completion_date type="Actual">April 2009</completion_date>
  <primary_completion_date type="Actual">March 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary end point of the study is a combined endpoint of cardiac death, myocardial infarction related to the target vessel or revascularization related to the target lesion.</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>In-segment binary restenosis at follow-up angiography</measure>
    <time_frame>6-8 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Late Lumen Loss at follow-up angiography</measure>
    <time_frame>6-8 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All cause mortality.</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of stent thrombosis (by ARC definition)</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">2600</enrollment>
  <condition>Coronary Heart Disease</condition>
  <arm_group>
    <arm_group_label>BPRES</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>biodegradable polymer rapamycin-eluting stent</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PPRES</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>permanent polymer rapamycin-eluting stent</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PPEES</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>permanent polymer everolimus-eluting stent</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>biodegradable polymer Rapamycin-eluting stent</intervention_name>
    <description>due to randomization, rapamycin-eluting stent with biodegradable polymer will be implanted</description>
    <arm_group_label>BPRES</arm_group_label>
    <other_name>ISAR stent</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>permanent polymer rapamycin-eluting stent (Cypher)</intervention_name>
    <description>due to randomization, rapamycin-eluting stent with permanent polymer will be implanted</description>
    <arm_group_label>PPRES</arm_group_label>
    <other_name>Cypher</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>permanent polymer everolimus-eluting stent (Xience, Promus)</intervention_name>
    <description>due to randomization, everolimus-eluting stent with permanent polymer will be implanted</description>
    <arm_group_label>PPEES</arm_group_label>
    <other_name>Xience</other_name>
    <other_name>Promus</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients older than age 18 with ischemic symptoms or evidence of myocardial ischemia&#xD;
             in the presence of ≥ 50% de novo stenosis located in native coronary vessels.&#xD;
&#xD;
          -  Written, informed consent by the patient or her/his legally-authorized representative&#xD;
             for participation in the study.&#xD;
&#xD;
          -  In women with childbearing potential a negative pregnancy test is mandatory&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Target lesion located in the left main trunk.&#xD;
&#xD;
          -  Target lesion located in the bypass graft.&#xD;
&#xD;
          -  In-stent restenosis.&#xD;
&#xD;
          -  Cardiogenic shock.&#xD;
&#xD;
          -  Malignancies or other comorbid conditions (for example severe liver, renal and&#xD;
             pancreatic disease) with life expectancy less than 12 months or that may result in&#xD;
             protocol non-compliance.&#xD;
&#xD;
          -  Known allergy to the study medications: Clopidogrel, Rapamycin, Everolimus, stainless&#xD;
             steel or cobalt chrome.&#xD;
&#xD;
          -  Inability to take clopidogrel for at least 6 months.&#xD;
&#xD;
          -  Pregnancy (present, suspected or planned) or positive pregnancy test.&#xD;
&#xD;
          -  Previous enrollment in this trial.&#xD;
&#xD;
          -  Patient's inability to fully cooperate with the study protocol&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Albert Schoemig, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Deutsches Herzzentrum Muenchen</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Adnan Kastrati, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Deutsches Herzzentrum Muenchen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medizinische Klinik, Klinikum rechts der Isar</name>
      <address>
        <city>Muenchen</city>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Deutsches Herzzentrum Muenchen</name>
      <address>
        <city>Munich</city>
        <zip>80636</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <results_reference>
    <citation>Byrne RA, Kastrati A, Kufner S, Massberg S, Birkmeier KA, Laugwitz KL, Schulz S, Pache J, Fusaro M, Seyfarth M, Schömig A, Mehilli J; Intracoronary Stenting and Angiographic Results: Test Efficacy of 3 Limus-Eluting Stents (ISAR-TEST-4) Investigators. Randomized, non-inferiority trial of three limus agent-eluting stents with different polymer coatings: the Intracoronary Stenting and Angiographic Results: Test Efficacy of 3 Limus-Eluting Stents (ISAR-TEST-4) Trial. Eur Heart J. 2009 Oct;30(20):2441-9. doi: 10.1093/eurheartj/ehp352. Epub 2009 Aug 30.</citation>
    <PMID>19720642</PMID>
  </results_reference>
  <verification_date>March 2010</verification_date>
  <study_first_submitted>January 10, 2008</study_first_submitted>
  <study_first_submitted_qc>January 21, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 22, 2008</study_first_posted>
  <last_update_submitted>March 12, 2010</last_update_submitted>
  <last_update_submitted_qc>March 12, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 15, 2010</last_update_posted>
  <responsible_party>
    <name_title>Prof. A. Schömig</name_title>
    <organization>Deutsches Herzzentrum Munich</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Everolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

